Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Pancreatic Cancer Cachexia: The Role of Nutritional Interventions.

Mitchell T, Clarke L, Goldberg A, Bishop KS.

Healthcare (Basel). 2019 Jul 9;7(3). pii: E89. doi: 10.3390/healthcare7030089. Review.

2.

Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study.

Yogaratnam J, Rito J, Kakuda TN, Fennema H, Gupta K, Jekle CA, Mitchell T, Boyce M, Sahgal O, Balaratnam G, Chanda S, Van Remoortere P, Symons JA, Fry J.

J Infect Dis. 2019 Jan 7;219(2):177-185. doi: 10.1093/infdis/jiy410.

PMID:
30053042
3.

Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults.

Kakuda TN, Yogaratnam J, Rito J, Boyce M, Mitchell T, Gupta K, Symons JA, Chanda S, Van Remoortere P, Fry J.

Antivir Ther. 2018;23(7):555-566. doi: 10.3851/IMP3244. Epub 2018 Jun 21.

PMID:
29927386
4.

Response: Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity.

Boyce M, van den Berg F, Mitchell T, Darwin K, Warrington S.

Eur J Clin Pharmacol. 2017 Jul;73(7):925. doi: 10.1007/s00228-017-2241-3. Epub 2017 Apr 1. No abstract available.

PMID:
28365794
5.

Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity.

Boyce M, van den Berg F, Mitchell T, Darwin K, Warrington S.

Eur J Clin Pharmacol. 2017 Feb;73(2):129-139. doi: 10.1007/s00228-016-2150-x. Epub 2016 Oct 29.

PMID:
27796466
6.

Sample size calculation for the Power Model for dose proportionality studies.

Sethuraman VS, Leonov S, Squassante L, Mitchell TR, Hale MD.

Pharm Stat. 2007 Jan-Mar;6(1):35-41.

PMID:
17323313

Supplemental Content

Loading ...
Support Center